ClinicalTrials.gg
Status unknownNCT04298398MindGAP-PUpdated Oct 22, 2020

Impact of Group Psychological Interventions on Extracellular Vesicles in People Who Had Cancer

An interventional study of Mindfulness Based-Cognitive Therapy (MBCT) and Emotion Focused Therapy Group for Cancer Recovery (EFT-CR) in Cancer, sponsored by Instituto Portugues de Oncologia, Francisco Gentil, Porto. Status unknown. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-10-22.

Primary conditionProstatic NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Prostatic Neoplasms
Why
  1. The study's title name Prostatic Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Instituto Portugues de Oncologia, Francisco Gentil, Porto · Not applicable, Interventional, and Supportive care

How we know

The sponsor has not verified this record recently (last verified Oct 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Background: There is some evidence demonstrating the effect of psychological interventions in improvements in health biological parameters. To best of our knowledge, no study had addressed the impact of any psychological intervention on extracellular vesicles. In addition, Mindfulness-Based Cognitive Therapy (MBCT) and Emotion Focused Therapy for Cancer Recovery (EFT-CR) in the group have never been explored regarding extracellular vesicles and the effectiveness of these was not compared yet.

Objectives:

  1. To explore and compare the effect of MBCT and EFT-CR on biological parameters and psychological variables in distressed people who have had breast, prostate and colorectal cancer;
  2. In addition, we will explore the acceptability through recruitment and retention rates of MBCT and EFT-CR in group and evaluate whether these interventions are appropriate for a larger clinical trial.

Methods: The design of this study is a parallel randomized controlled trial. Participants will be randomized into MBCT, EFT-CR or usual care. Outcome measures will be assessed before, at the end of the intervention (8 weeks) and follow-ups (24 and 52 weeks from the baseline moment).

Hypotheses: The researchers expected that both interventions will have an effect on extracellular vesicles and other study biomarkers as well as improvements in psychological outcomes, compared to treatment as usual (TAU) group. Regarding the comparative effectiveness, we did not have evidence to hypothesize which one of the interventions will be superior in both biological (extracellular vesicles) and psychological outcomes.

Contribution for practice: The results of this preliminary study would permit to know if there are benefits of these psychological interventions on changes in extracellular vesicles and on psychological outcomes related to health. In addition, this study will permit to determine the acceptability of conducting a larger randomized controlled trial.

02

Conditions studied

  • Cancer

Keywords

  • Breast cancer
  • Prostate cancer
  • Colorectal cancer
  • Psychological stress
  • Anxiety
  • Depression
  • Emotion Focused Therapy
  • Distress
  • Extracellular vesicles
  • Exosomes
  • Biomarkers
  • Inflammatory response genes
  • Group interventions
  • Mindfulness
  • Mindfulness Based Cognitive Therapy
03

In context

Prostatic Neoplasms Reclassified

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

This study's planned enrollment of 108 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Instituto Portugues de Oncologia, Francisco Gentil, Porto is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Compared within Prostatic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women
  • Aged 18 to 65
  • Diagnosed with breast, prostate, or colorectal cancer
  • Have been diagnosed with cancer stage I-III
  • Have finished cancer treatments from 3 months to 2 years (it will be included ongoing hormonal therapies)
  • Experiencing significant distress (5 or more) on the Distress Thermometer at baseline
  • Available to attend the intervention for the trial duration
  • Sufficient functional ability to participate in intervention groups ()
  • Ability to speak and write Portuguese and literacy to autonomous completion of questionnaires

Exclusion criteria

Exclusion Criteria:

  • Patients in treatments such as ongoing chemotherapy or radiotherapy, or trastuzumab therapy
  • Patients with ostomy
  • A diagnosis of a concurrent disorder of psychosis, substance abuse, bipolar disorder, or active suicidality
  • Current use of antipsychotics
  • Current use of anti-inflammatory medication (corticotherapy)
  • Currently engaging in a mindfulness meditation practice or yoga, or having done so within the previous year
  • Being under any actual psychosocial or psychological treatment
  • Participation in a MBCT program in the last five years
  • Pregnancy or breast feeding
  • A diagnosis of a concurrent disorder

Study Population Description: Participants will be recruited in the Portuguese Oncology Institute of Porto (Porto, Portugal), which is a reference public hospital in the north of the country offering cancer treatments.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Mindfulness (MBCT)

    Group therapy based on Mindfulness Based-Cognitive Therapy (MBCT).

    Behavioral: Mindfulness Based-Cognitive Therapy (MBCT)

  • Experimental
    Emotion Focused Therapy (EFT-CR)

    Group therapy based on Emotion Focused Therapy for Cancer Recovery (EFT-CR).

    Behavioral: Emotion Focused Therapy Group for Cancer Recovery (EFT-CR)

  • Other
    Control Group

    Treatment as Usual is the condition in which participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral and intervention for people identified with significant distress difficulties.

    Other: Treatment as usual (no intervention)

Interventions

  • BehavioralMindfulness Based-Cognitive Therapy (MBCT)

    MBCT is a program developed by Zindel Segal, Mark Williams and John Teasdale. During MBCT patients learn to decenter their negative thoughts and feelings, allowing the mind to move from an automatic thought pattern to conscious emotional processing. Mindfulness practices included in this program are breath awareness, body scan, sitting and walking meditation, and mindful yoga. The intervention will have the following structure: 8 weekly face-to-face meetings of 2 hours in a group format, daily home-based practice of learned skills, 4 hours of retreat/intensive group work after the fifth week, 6 months of home practice, 4 monthly consolidation face-to-face sessions.

  • BehavioralEmotion Focused Therapy Group for Cancer Recovery (EFT-CR)

    EFT-CR is an evidence-based approach to psychotherapy, which combines aspects of person-centered, gestalt and existential therapies with contemporary emotion theory and dialectical constructivism (Elliott et al, 2004, Rice \& Greenberg, 1984). On EFT-CR, therapist follows the client experience and guides the process, proposing therapeutic tasks when specific client behaviors occur. EFT-CR uses a set of emotion change principles which guide a process of emotional deepening process, from undifferentiated distress to secondary reactive emotions to primary maladaptive emotions to core pain and thence to primary adaptive emotions and emotional transformation (Elliott \& Greenberg 2016). The intervention will have the following structure: 8 weekly face-to-face meetings of 2 hours in a group format, daily home-based practice of learned skills, 4 hours of retreat/intensive group work after the fifth week, 6 months of home practice, 4 monthly consolidation face-to-face sessions.

  • OtherTreatment as usual (no intervention)

    Treatment as Usual is the condition in which participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral and intervention for people identified with significant distress difficulties.

06

What researchers measure

Primary outcomes

  1. Change on Extracellular vesicles number by ultracentrifugation with sucrose cushion

    The collected extracellular vesicles will be quantified by Nanoparticle tracking analysis (Nanosight Ltd.), and data will be measured in particles per milliliter (mL). NTA measures Brownian movements on a particle-by-particle basis tracking movements by image analysis. Additionally, miR21-5p - a brain related microRNA - will be measured to ascertain for the extracellular vesicle's origin. The latter will be achieved by isothermal DNA amplification method, and data will be measured by luminescence (in RLU - relative light unit).

    Time frame: T0-before intervention; T1-8 weeks after T0; T2-24 weeks after T0; T3-52 weeks after T0

  2. Change on anxiety, depression and stress (Depression Anxiety Stress Scales, DASS21)

    This self-report instrument assess the depressive, anxiety and stress symptoms in a 4-points likert scale, from 0 to 3, with higher values representing higher depression, anxiety and stress symptoms

    Time frame: T0-before intervention; T1-8 weeks after T0; T2-24 weeks after T0; T3-52 weeks after T0

Secondary outcomes

  1. Change on Cancer antigen (CA 15-3)

    This indicator assess CA 15-3 (units/mL) using an immunoassay analyzer

    Time frame: T0-before intervention;T2-24 weeks after T0; T3-52 weeks after T0

  2. Change on Prostate-specific antigen (PSA)

    This indicator assess PSA (ng/mL) using an immunoassay analyzer

    Time frame: T0-before intervention;T2-24 weeks after T0; T3-52 weeks after T0

  3. Change on Carcinoembryonic Antigen assays (CEA)

    This indicator assess CEA (ng/mL) using an immunoassay analyzer

    Time frame: T0-before intervention;T2-24 weeks after T0; T3-52 weeks after T0

  4. Change on Adrenocorticotropic Hormone (ACTH)

    This indicator assess ACTH (pg/mL) using an immunoassay analyzer

    Time frame: T0-before intervention;T2-24 weeks after T0; T3-52 weeks after T0

  5. Transcript inflammatory response genes (IL-1, IL-6, IL-8, IL-10, IFNγ and TNF)

    These indicators assess inflammatory response genes in plasma by Quantitative RT-PCR assays of the same individuals using TaqMan™ Gene Expression Assays

    Time frame: T0-before intervention; T2-24 weeks after T0; T3-52 weeks after T0

  6. Change on Analytic biomarkers (Erythrocytes number)

    This indicator assess erythrocytes number (million/mm3) from blood samples(Sysmex XN)

    Time frame: T0-before intervention; T2-24 weeks after T0; T3-52 weeks after T0

  7. Change on Analytic biomarkers (PCR number)

    This indicator assess PCR (mg/L) from blood samples

    Time frame: T0-before intervention; T2-24 weeks after T0; T3-52 weeks after T0

  8. Change on Analytic biomarkers (telomerase activity)

    This indicator assess telomerase activity (units) from blood samples

    Time frame: T0-before intervention; T2-24 weeks after T0; T3-52 weeks after T0

  9. Change on Analytic biomarkers (hemoglobin glycosylated (HPLC))

    This indicator assess HPLC (mmol/mol) from blood samples

    Time frame: T0-before intervention; T2-24 weeks after T0; T3-52 weeks after T0

  10. Change on Global distress (Clinical Outcome Routine Evaluation - Outcome Measure, CORE-OM)

    This self-report measure assesses global distress in four domains: subjective well-being, symptoms, social/life functioning, risk to self and others, rated in 5-points likert scale from never to always. Higher scores meaning higher psychological suffering

    Time frame: T0-before intervention; T1-8 weeks after T0; T2-24 weeks after T0; T3-52 weeks after T0

  11. Change on quality of life (Functional Assessment of Cancer Therapy, FACT)

    These self-report instrument assess perceived quality of life related to the cancer, in a 5-points likert scale, from 0 to 4, with higher value indicated higher quality of life

    Time frame: T0-before intervention; T2-24 weeks after T0; T3-52 weeks after T0

  12. Change on quality of life (Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being Scale, FACIT-SP)

    These self-report instruments assess perceived spiritually related to the cancer in a 5-points likert scale, from 0 to 4, with higher value indicated higher well-being

    Time frame: T0-before intervention; T2-24 weeks after T0; T3-52 weeks after T0

  13. Change on fear of cancer recurrence (Fear of Cancer Recurrence, FCR-7)

    This self-report instrument assess the fear of cancer recurrence, rated in a 5-points likert scale, with higher values indicated higher fear of recurrence

    Time frame: T0-before intervention; T1-8 weeks after T0; T2-24 weeks after T0; T3-52 weeks after T0

  14. Change on satisfaction perceived social support (ESSS)

    This self-report instrument assess the perceived level of social support, rated in a 5-points likert scale, with higher values meaning higher social support

    Time frame: T0-before intervention; T1-8 weeks after T0; T2-24 weeks after T0; T3-52 weeks after T0

  15. Change on emotional regulation processes (Emotion Regulation Questionnaire, ERQ, emotion suppression subscale)

    This self-report measure assess the emotion regulation processes rated in a 7-points likert scale, with higher values representing higher emotional suppression

    Time frame: T0-before intervention; T1-8 weeks after T0; T2-24 weeks after T0; T3-52 weeks after T0

  16. Change on impact of events (Impact of Event Scale - Revised, IES-R)

    This self-report measure assess the impact of significant events, rated in a 5-points likert scale, with higher scores meaning higher negative impact of the event

    Time frame: T0-before intervention; T1-8 weeks after T0; T2-24 weeks after T0; T3-52 weeks after T0

  17. Change on Mindfulness Attention and Awareness (Mindfulness Attention and Awareness Scale, MAAS)

    This self-report measure assess the mindfulness and awareness skills, rated in a 6-points likert scale with higher scores indicating higher attention and awareness

    Time frame: T0-before intervention; T1-8 weeks after T0; T2-24 weeks after T0; T3-52 weeks after T0

  18. Change on self-compassion skills (Self-Compassion Scale - Short Form, SHORT FORM)

    This self-report measure assess the self-compassion skills, rated in 5-points likert scale, with higher scores indicating higher self-compassion

    Time frame: T0-before intervention; T1-8 weeks after T0; T2-24 weeks after T0; T3-52 weeks after T0

  19. Change Interview (Elliot, 1999)

    This interview assesses the psycho-therapeutic changes perceived by participants after psychological intervention. The interview questions explore the changes that a person has noticed since therapy began, what the person attributes these changes to, and helpful and unhelpful aspects of therapy, in a qualitative way. In addition, the participants identified therapeutic changes as result of the therapy and are asked to rate these changes in three scales: expected change (1: change totally expected; 5: totally unexpected); change without therapy (1: the change would not have happened; 5: change would happen for sure); and the value of the change (1: nothing important; 5: extremely important).

    Time frame: T2-24 weeks after T0

  20. Change on smoking dependency (Fagestrom Test)

    This instrument assesses nicotine dependency with 6 items (rated from 0 to 2 or 3). The total score range is 1-10, with higher values meaning higher nicotine dependency

    Time frame: T0-before intervention; T2-24 weeks after T0; T3-52 weeks after T0

  21. Change on physical activity (IPAQ,The International Physical Activity Questionnaire)

    This instrument assesses physical activity in 7 items, with higher scores meaning higher level of physical activity

    Time frame: T0-before intervention; T2-24 weeks after T0; T3-52 weeks after T0

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2021; primary completion for Sep 2021, 0 months later.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 0 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2020
First posted
Mar 6, 2020
StartEst.
Sep 1, 2021
Primary completionEst.
Sep 2021
CompletionEst.
Sep 2021
Last update
Oct 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04298398
Lead sponsor
Instituto Portugues de Oncologia, Francisco Gentil, Porto
Collaborators
Polytechnic Institute of Porto, VTT Technical Research Centre, Finland, University of Oulu, Linnaeus University, European Commission
Responsible party
Sponsor
First posted
Mar 6, 2020
Start date
Sep 1, 2021 (estimated)
Primary completion
Sep 2021 (estimated)
Completion
Sep 2021 (estimated)
Last update
Oct 22, 2020

Study contacts

Eunice Silva, PhD
Contact
esilva@ipoporto.min-saude.pt
00351 961761035 ext. 7808
Carmen Jerónimo, PhD
Contact
carmenjeronimo@ipoporto.min-saude.pt
00351 225084000 ext. 1952
Rui Henrique, PhD
study chair · IPO-Porto
Carmen Jerónimo, PhD
study director · IPO-Porto
Eunice Silva, PhD
study director · IPO-Porto
Goreti Sales, PhD
study director · ISEP-Biomark (Polytecnic Institute of Porto)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion